Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)

Inclusion Criteria: * Participants with cirrhosis of the liver * Participants with clinically evident ascites primarily managed by diet and/or diuretics * Stable treatment of ascites for at least the previous 2 weeks without paracentesis * Participants having undergone no more than one therapeutic paracentesis in the previous 6 months. Exclusion Criteria: * Participants with an existing functional transjugular intrahepatic portosystemic shunt (TIPS) or other shunt * Known hepatocellular carcinoma * Participants with ascites of cardiac origin or due to peritoneal infection (e.g. tuberculosis) or peritoneal carcinoma * Participants previously exposed to satavaptan in the past 12 months